A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

Early Parkinson's Disease Clinical Trial

Official title:

A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00537485
• Other study ID #: 243-07-001
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: September 27, 2007
• Last updated: February 3, 2014
• Start date: September 2007
• Est. completion date: December 2009

Study information

• Verified date: February 2014
• Source: Otsuka Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

To investigate superiority of SPM 962 over placebo in early Parkinson's disease patients in a multi-center, placebo-controlled, double-blind study following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12-week dose titration/maintenance period)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 180
• Est. completion date: December 2009
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years to 79 Years

Eligibility

Inclusion Criteria:

1. Subject diagnosed as having Parkinson's disease in accordance with "Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)"

2. Subject is 30 years < > 80 years at the time of informed consent

3. Hoehn & Yahr stage 1- 3

4. Total of each sum score of UPDRS Part 2 and 3 is over 10 at screening test

Exclusion Criteria:

1. Subject has previously participated in a trial with SPM 962

2. Subject is on L-dopa treatment for total of over 6 months at the time of informed consent

3. Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior at screening test and baseline

4. Subject has orthostatic hypotension

5. Subject has a history of epilepsy, convulsion and other

6. Subject has a complication of serious cardiac disorder/arrhythmia or has the history

7. Subject has arrhythmia and treated with class 1a anti-arrhythmic drugs (e.g. quinidine, procainamide etc.) or class 3 anti-arrhythmic drugs (e.g. amiodarone, sotalol etc.)

8. Subject has serious ECG abnormal at screening i.e.; 1) Subject has more than 450 msec of QTc values both in two measurements at screening test 2) Subject has more than 470 msec for females and more than 450 msec for males of mean QTc values of two measurements at baseline

9. Subject has congenital long QT syndrome

10. Subject has serum potassium of less than 3.5 mEq/L at screening test.

11. Subject has total bilirubin of 3.0 mg/dL and above or AST(GOT), ALT(GPT) greater than 2.5 times (or 100 IU/L and above) of the clinical laboratory's upper limit of the reference range at screening test

12. Subject has 30 mg/dL and above of BUN or 2.0 mg/dL and above of serum creatinine at screening test

13. Subject has a history of allergy to topical medicine, e.g. transdermal patch

14. Subject is pregnant, nursing, or is child bearing potential while the trial

15. Subject is receiving therapy with prohibited drug specified in the study protocol

16. Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant

17. Subject has dementia

18. Subject is unable to give consent

19. Subject is participating in another trial of an investigational drug or done so within 12 weeks prior to the initial treatment

20. Investigator judges that subject is inappropriate as a study subject with other reasons

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Early Parkinson's Disease
• Parkinson Disease

Intervention

Drug:
• SPM 962
transdermal application, 1 time per day
• placebo
transdermal application, 1 time per day

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Otsuka Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3	Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 2 and Part 3.; UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.	baseline, end of maintenance period	No
Secondary	Efficacy Rate in Total of Each Sum Score of UPDRS Part 2 and Part 3	Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in total of each sum score of UPDRS Part 2 and Part 3 at the end of maintenance period	baseline, end of maintenance period	No
Secondary	Mean Change in UPDRS Part 2 Sum Score	Mean change (LOCF) from baseline in UPDRS Part 2 sum score at every two weeks after dosing.; UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.	Baseline, every two weeks	No
Secondary	Efficacy Rate in UPDRS Part 2 Sum Score	Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.	Baseline, every two weeks	No
Secondary	UPDRS Part 3 Sum Score	Mean change (LOCF) from baseline in UPDRS Part 3 sum score at every two weeks after dosing.; UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.	Baseline, every two weeks	No
Secondary	Efficacy Rate in UPDRS Part 3 Sum Score	Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.	Baseline, every two weeks	No
Secondary	UPDRS Part 1 Sum Score	MMean change (LOCF) from baseline in UPDRS Part 1 sum score at every two weeks after dosing.; UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.	Baseline, every two weeks	No
Secondary	UPDRS Part 4 Sum Score	Mean change (LOCF) from baseline in UPDRS Part 4 sum score at every two weeks after dosing.; UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.	Baseline, every two weeks	No
Secondary	Total of Each Sum Score of UPDRS Part 1, 2, 3, and 4	Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 1, 2, 3 and 4.; UPDRS sub-scale Part 1, 2, 3, and 4 assess 4, 13, 14, and 11 items respectively. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.	Baseline, every two weeks	No
Secondary	The Modified Hoehn and Yahr Stage	Mean change (LOCF) from baseline in the Modified Hoehn and Yahr Severity of Illness at the end of maintenance period. The Modified Hoehn and Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.	Baseline, end of maintenance period	No